Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Bullboard Posts
Post by pennyDoctoron Mar 05, 2020 2:22pm
209 Views
Post# 30771641

Horizon coming into focus

Horizon coming into focusMarket negative today! Sirona filling the gap and pushing off lows.  

Regarding yesterday news the reason for listing Huaxi pharmaceutical on the Hong Kong exchange may be to wholly buy out Sirona.  
I read that Hauxi has 9000 sq meters for production that is idle and looking for partners they already have sufficient capacity to take on Sirona production without spending any capital.

My hunch is the Merger with Sirona is the game plan.  Stupid North American investors dont see the value but the China does.

Here is the excerpt from the news release that has me buying more.

"....Once Huaxipharm is publicly listed, Sirona management anticipates the relationship going well beyond the service and development agreement

This is on their website
https://www.huaxipharm.com/en/HuaxiRoad/HuaxiRoad.asp 


Huaxipharm Co., Ltd

www.huaxipharm.com/en/HuaxiRoad/HuaxiRoad.asp

HuaXi Pharm. intend to build R&D dominated modern pharmaceutical group, keep improving innovation of Chinese drug technology market. Now we honestly invite lites of drug industry and business to join us... make designs of company mergers, acquisitions, restructuring, and investment and financing and other related scheme; ...

We are in for a great year in my opinion hold your shares and ignore negative opinion things are going to happen more quickly.


Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse